Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
18.6M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
14.4M
-
Shares change
-
+4.85M
-
Total reported value, excl. options
-
$19.9M
-
Value change
-
+$6.69M
-
Number of buys
-
14
-
Number of sells
-
-1
-
Price
-
$1.38
Significant Holders of UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) as of Q1 2024
21 filings reported holding UNCY - UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q1 2024.
UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.4M shares
of 18.6M outstanding shares and own 77.73% of the company stock.
Largest 10 shareholders include BVF INC/IL (3.61M shares), RA CAPITAL MANAGEMENT, L.P. (3.47M shares), Vivo Capital, LLC (3.47M shares), Rosalind Advisors, Inc. (1.88M shares), Monashee Investment Management LLC (1M shares), VANGUARD GROUP INC (340K shares), GEODE CAPITAL MANAGEMENT, LLC (253K shares), GOLDMAN SACHS GROUP INC (93.3K shares), RENAISSANCE TECHNOLOGIES LLC (92.9K shares), and CITADEL ADVISORS LLC (69.4K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.